LONDON (Dow Jones)--GlaxoSmithKline PLC’s (GSK) Chief Executive Andrew Witty had his remuneration cut by 24% last year because the U.K.'s biggest drug maker missed its profit targets.
LONDON (Dow Jones)--GlaxoSmithKline PLC’s (GSK) Chief Executive Andrew Witty had his remuneration cut by 24% last year because the U.K.'s biggest drug maker missed its profit targets.
